Products
Codrituzumab Biosimilar Monoclonal Antibody (GPC3) for Research
Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-114-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody |
| INN Name | Codrituzumab |
| Target | GPC3 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Perseus Proteomics;Chugai Pharmaceutical;Roche |
| Conditions Approved | na |
| Conditions Active | Liver cancer |
| Conditions Discontinued | na |
| Development Tech | na |
About target - GPC3
1. Protein Glypican-3
2. Gene GPC3
3. Organism Homo sapiens (Human)
Function
Cell surface proteoglycan that bears heparan sulfate (PubMed:14610063).
Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity).
Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation (By similarity).
Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands (PubMed:16227623, PubMed:24496449).
Positively regulates the non-canonical Wnt signaling pathway (By similarity).
Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression (By similarity).
Inhibits the dipeptidyl peptidase activity of DPP4 (PubMed:17549790).
Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4 (By similarity).
Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis (By similarity).
Required for coronary vascular development (By similarity).
Plays a role in regulating cell movements during gastrulation (By similarity).
Miscellaneous
Used as a marker for hepatocellular carcinoma (HCC) as it is expressed in HCC but is not detectable in hepatocytes from normal or benign liver diseases (PubMed:12851874). When attached to the cell surface, stimulates the growth of HCC cells by increasing canonical Wnt signaling (PubMed:16024626). Cleavage is not required for stimulation of Wnt signaling or HCC growth (PubMed:16227623).
